PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-2.29
Negative P/E while Drug Manufacturers - Specialty & Generic median is -0.87. Seth Klarman would scrutinize path to profitability versus peers.
5.95
P/S 1.1-1.25x Drug Manufacturers - Specialty & Generic median of 4.80. John Neff would demand superior growth or margins to justify premium.
0.33
P/B less than half the Drug Manufacturers - Specialty & Generic median of 1.18. Joel Greenblatt would investigate if assets are truly impaired. Check ROE versus peers.
35.16
P/FCF of 35.16 versus zero FCF in Drug Manufacturers - Specialty & Generic. Walter Schloss would verify cash flow quality.
25.15
P/OCF of 25.15 versus zero operating cash flow in Drug Manufacturers - Specialty & Generic. Walter Schloss would verify operational quality.
0.33
Fair value ratio less than half the Drug Manufacturers - Specialty & Generic median of 1.18. Joel Greenblatt would investigate if this discount is justified.
-10.93%
Negative earnings while Drug Manufacturers - Specialty & Generic median yield is -1.11%. Seth Klarman would investigate path to profitability.
2.84%
FCF yield of 2.84% versus zero FCF in Drug Manufacturers - Specialty & Generic. Walter Schloss would verify cash flow quality.